$NTRA
Natera, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023008938 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $261.4M $241.8M $194.1M
YoY Change 31.89% 24.53% 27.45%
Cost Of Revenue $143.1M $148.1M $103.2M
YoY Change 31.04% 43.51% 54.51%
Gross Profit $118.3M $93.63M $90.92M
YoY Change 32.93% 2.99% 6.34%
Gross Profit Margin 45.24% 38.73% 46.83%
Selling, General & Admin $152.5M $149.6M $147.6M
YoY Change 2.03% 1.35% 36.28%
% of Gross Profit 128.97% 159.8% 162.38%
Research & Development $78.17M $82.31M $80.41M
YoY Change -5.34% 2.35% 100.09%
% of Gross Profit 66.11% 87.9% 88.45%
Depreciation & Amortization $5.124M $5.077M $3.002M
YoY Change 10.69% 69.12% 17.77%
% of Gross Profit 4.33% 5.42% 3.3%
Operating Expenses $230.7M $231.9M $228.0M
YoY Change -0.59% 1.7% 53.55%
Operating Profit -$112.4M -$138.3M -$137.1M
YoY Change -21.43% 0.85% 117.61%
Interest Expense -$3.177M $3.061M $2.087M
YoY Change -247.77% 46.67% 0.68%
% of Operating Profit
Other Income/Expense, Net $4.518M $4.585M $801.0K
YoY Change 1531.05% 472.41% -42.79%
Pretax Income -$111.1M -$136.8M -$138.4M
YoY Change -23.37% -1.18% 117.23%
Income Tax -$282.0K $160.0K $179.0K
% Of Pretax Income
Net Earnings -$110.8M -$136.9M -$138.6M
YoY Change -23.66% -1.23% 117.06%
Net Earnings / Revenue -42.39% -56.63% -71.39%
Basic Earnings Per Share -$0.97 -$1.23 -$1.45
Diluted Earnings Per Share -$0.97 -$1.23 -$1.45
COMMON SHARES
Basic Shares Outstanding 114.3M 113.3M 95.58M
Diluted Shares Outstanding 113.7M 111.8M 95.58M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $735.9M $812.0M $752.0M
YoY Change 15.23% 7.99% 15.05%
Cash & Equivalents $381.1M $403.2M $158.3M
Short-Term Investments $354.8M $408.9M $593.7M
Other Short-Term Assets $26.82M $29.99M $35.36M
YoY Change 11.15% -15.19% 32.92%
Inventory $42.69M $40.68M $25.05M
Prepaid Expenses
Receivables $260.1M $246.8M $167.9M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $1.066B $1.129B $980.2M
YoY Change 18.19% 15.23% 23.86%
LONG-TERM ASSETS
Property, Plant & Equipment $164.9M $100.6M $78.36M
YoY Change 101.61% 28.36% 95.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $17.52M $19.29M $21.68M
YoY Change -18.53% -11.02% 74.72%
Total Long-Term Assets $182.4M $189.4M $164.4M
YoY Change 10.25% 15.19% 61.04%
TOTAL ASSETS
Total Short-Term Assets $1.066B $1.129B $980.2M
Total Long-Term Assets $182.4M $189.4M $164.4M
Total Assets $1.248B $1.319B $1.145B
YoY Change 16.96% 15.22% 28.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.11M $36.12M $18.07M
YoY Change -25.13% 99.91% 285.95%
Accrued Expenses $144.2M $143.6M $130.9M
YoY Change 3.33% 9.68% 69.37%
Deferred Revenue $15.64M $16.58M $13.91M
YoY Change -2.28% 19.15% 53.42%
Short-Term Debt $80.42M $80.40M $50.10M
YoY Change 60.51% 60.48% 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $276.9M $291.0M $231.1M
YoY Change 10.03% 25.92% 38.39%
LONG-TERM LIABILITIES
Long-Term Debt $282.3M $282.0M $280.7M
YoY Change 0.45% 0.45% 0.43%
Other Long-Term Liabilities $92.60M $95.37M $2.531M
YoY Change 2459.29% 3667.88% -96.61%
Total Long-Term Liabilities $374.9M $377.3M $2.531M
YoY Change 10261.8% 14808.65% -99.29%
TOTAL LIABILITIES
Total Short-Term Liabilities $276.9M $291.0M $231.1M
Total Long-Term Liabilities $374.9M $377.3M $2.531M
Total Liabilities $651.7M $668.3M $602.3M
YoY Change 4.72% 10.95% 15.6%
SHAREHOLDERS EQUITY
Retained Earnings -$2.200B -$2.100B -$1.500B
YoY Change 29.41% 40.0% 51.98%
Common Stock $2.796B $2.742B $2.090B
YoY Change 30.67% 31.21% 54.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $596.1M $650.6M $542.3M
YoY Change
Total Liabilities & Shareholders Equity $1.248B $1.319B $1.145B
YoY Change 16.96% 15.22% 28.11%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$110.8M -$136.9M -$138.6M
YoY Change -23.66% -1.23% 117.06%
Depreciation, Depletion And Amortization $5.124M $5.077M $3.002M
YoY Change 10.69% 69.12% 17.77%
Cash From Operating Activities -$78.39M -$80.89M -$137.3M
YoY Change -29.29% -41.08% 83.34%
INVESTING ACTIVITIES
Capital Expenditures $8.968M $11.60M $15.89M
YoY Change -215.33% -26.99% 54.82%
Acquisitions
YoY Change
Other Investing Activities $56.00M $27.25M $222.9M
YoY Change 31.56% -87.78% 129.81%
Cash From Investing Activities $47.03M $15.65M $207.0M
YoY Change 35.19% -92.44% 138.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.312M 2.301M 4.156M
YoY Change 4.42% -44.63% -9.06%
NET CHANGE
Cash From Operating Activities -78.39M -80.89M -137.3M
Cash From Investing Activities 47.03M 15.65M 207.0M
Cash From Financing Activities 9.312M 2.301M 4.156M
Net Change In Cash -22.04M -62.94M 73.91M
YoY Change -67.17% -185.15% 349.75%
FREE CASH FLOW
Cash From Operating Activities -$78.39M -$80.89M -$137.3M
Capital Expenditures $8.968M $11.60M $15.89M
Free Cash Flow -$87.35M -$92.49M -$153.2M
YoY Change -15.25% -39.61% 79.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
111767000
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
95578000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M6D
CY2023Q1 ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
-9200000
CY2022Q1 ntra Increase Decrease Net Income Loss
IncreaseDecreaseNetIncomeLoss
6400000
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37478
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
01-0894487
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
13011 McCallen Pass
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building A Suite 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78753
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
249-9090
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
NTRA
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114301688
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403154000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
408858000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
432301000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
5134000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
3830000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
246785000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5277000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q1 us-gaap Inventory Net
InventoryNet
40683000
CY2022Q4 us-gaap Inventory Net
InventoryNet
35406000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
29988000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
33634000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1129468000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1211817000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100587000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
69537000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
71874000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19288000
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18330000
CY2023Q1 us-gaap Assets
Assets
1318880000
CY2022Q4 us-gaap Assets
Assets
1394474000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
36123000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31148000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
39231000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
44010000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
118638000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113359000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111255000
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Natera, Inc.
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001604821
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16579000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
80398000
CY2022Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
80350000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
290969000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
310499000
CY2023Q1 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
281973000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
281653000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21511000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
73854000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q1 us-gaap Liabilities
Liabilities
668307000
CY2022Q4 us-gaap Liabilities
Liabilities
688730000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113359000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111255000
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2741932000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2664730000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2079572000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1942635000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11798000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
650573000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1318880000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1394474000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
194133000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82306000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
80414000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
149627000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
147634000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
380057000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
331263000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-138301000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-137130000
CY2023Q1 us-gaap Interest Expense
InterestExpense
3061000
CY2022Q1 us-gaap Interest Expense
InterestExpense
2087000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4585000
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
801000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-136777000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-138416000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
160000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
179000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-136937000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138595000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4564000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-11617000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-132373000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-150212000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111767000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95578000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
653304000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4156000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35087000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-11617000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-138595000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
542335000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
705744000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2301000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40695000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
4564000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-136937000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
650573000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-136937000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-138595000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5077000
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3002000
CY2023Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
2679000
CY2023Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
787000
CY2022Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
1790000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
40695000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
35087000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3806000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
3305000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
320000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
312000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-265000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
281000
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
-46000
CY2022Q1 ntra Amortization Of Other Assets
AmortizationOfOtherAssets
143000
CY2023Q1 ntra Non Cash Interest Expense
NonCashInterestExpense
48000
CY2022Q1 ntra Non Cash Interest Expense
NonCashInterestExpense
4000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2400000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
45788000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1860000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2338000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6366000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5762000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-7557000
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
14993000
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8545000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2177000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2765000
CY2023Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-18181000
CY2022Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
21336000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7312000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5735000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80890000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-137277000
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
24977000
CY2022Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
166895000
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
27250000
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
81000000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11598000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15885000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15652000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
207033000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2301000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4156000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2301000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4156000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-62937000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
73912000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
466091000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84614000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403154000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
158526000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1124000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
159000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1613000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2096000
CY2023Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
14435000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
19771000
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-136900000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2100000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
403200000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
408900000
CY2023Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
80400000
CY2023Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
70000000.0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13144500
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
35
CY2022Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
500000
CY2022Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
433200000
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"/>The preparation of financial statements in accordance with generally accepted accounting principles (“GAAP”) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, average selling price expected to be received from insurance payors, the operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The total consideration which the Company expects to be entitled to receive from patients and insurance carriers in exchange for the Company's products is a significant estimate determined by calculating the average selling price based on the contractual pricing agreed to with each insurance carrier for each test (CPT code) performed adjusted for variable consideration related to historical percent of cases allowed, historical percent of patient responsibility collected, and historical percent of contract price collected from insurance carriers. The Company uses the expected-value approach of estimating variable consideration.  The Company also considers recent trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or changes to insurance coverage.  For insurance carriers with similar reimbursement characteristics, the Company uses a portfolio approach to estimate the effects of variable consideration. The Company also applies a constraint to the estimated variable consideration when it assesses it is probable that a significant reversal in the amount of cumulative revenue may occur in future periods. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">When assessing the total consideration for insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Allowance for doubtful accounts</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The allowance for doubtful accounts for trade accounts receivable and other receivables is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as historical experience, credit quality, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">Appropriate provision has been made for lifetime expected credit losses in accordance with ASC Topic 326-20, <i style="font-style:italic;">Financial Instruments—Credit Losses</i> (“Topic 326”), for trade receivables and available-for-sale debt securities. The Company’s estimate of expected credit losses includes consideration of past events, current conditions and forecasts of future economic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Inventory</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products. However, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Investments and financial instruments</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Other accrued liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;background:#ffffff;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;">The Company's uses estimates, judgments, and assumptions in several areas including, but not limited to, estimates of progress to date for certain contracts with vendors, liabilities related to clinical trials, payroll and related expenses, marketing liabilities, reserves associated with insurance and general overpayments, tax-related liabilities, and other operating expenses. Estimates consist of historical trends, analytical procedures, review of supporting documentation, inquiries with supply partners and vendors, and other relevant assumptions. Although the Company believes its estimates, assumptions, and judgment are reasonable, it is based upon information presently available and are subject to change.</p>
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38090000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to credit risk consist of cash, accounts receivable and investments. The Company limits its exposure to credit loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company performs evaluations of financial conditions for insurance carriers, patients, clinics and laboratory partners and generally does not require collateral to support credit sales. For the three months ended March 31, 2023, and 2022, there were no customers exceeding 10% of total revenues on an individual basis. As of March 31, 2023 and December 31, 2022, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. </p>
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-16362000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2287000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11798000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-13904000
CY2023Q1 ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
-9200000
CY2023Q1 ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
-0.08
CY2022Q1 ntra Increase Decrease Revenues
IncreaseDecreaseRevenues
6400000
CY2022Q1 ntra Increase Decrease Net Income Loss Per Share
IncreaseDecreaseNetIncomeLossPerShare
0.06
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
194133000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
241756000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
194133000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
246785000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
244385000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
16579000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10777000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
21511000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
20001000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
30778000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
28722000
CY2023Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
12100000
CY2022Q1 ntra Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
10508000
CY2023Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-3988000
CY2022Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-3889000
CY2023Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-800000
CY2022Q1 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-884000
CY2023Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
38090000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34457000
CY2023Q1 us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
-4000000.0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
794300000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
11502000
CY2023Q1 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
782798000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
857357000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
16103000
CY2022Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
841255000
CY2023Q1 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
782798000
CY2022Q4 ntra Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
841255000
CY2023Q1 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings
0
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
56
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
408858000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
11502000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
92453000
CY2023Q1 us-gaap Depreciation
Depreciation
5100000
CY2022Q1 us-gaap Depreciation
Depreciation
3000000.0
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
349114000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
341858000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
71246000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
67000000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
420360000
CY2023Q1 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
408858000
CY2022Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
3830000
CY2021Q4 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2429000
CY2023Q1 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-1304000
CY2022Q1 us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
-331000
CY2022Q1 us-gaap Financing Receivable Allowance For Credit Losses Write Offs
FinancingReceivableAllowanceForCreditLossesWriteOffs
368000
CY2023Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
5134000
CY2022Q1 us-gaap Financing Receivable Allowance For Credit Losses
FinancingReceivableAllowanceForCreditLosses
2392000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
141200000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
128151000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
40613000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35698000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100587000
CY2023Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
14271000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2023Q1 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
13707000
CY2022Q4 ntra Accrued Charges For Outsourced Testing
AccruedChargesForOutsourcedTesting
17036000
CY2023Q1 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
15203000
CY2022Q4 ntra Accrued Testing And Laboratory Materials From Suppliers
AccruedTestingAndLaboratoryMaterialsFromSuppliers
13281000
CY2023Q1 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
7604000
CY2022Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
8943000
CY2023Q1 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
21793000
CY2022Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
36710000
CY2023Q1 ntra Accrued Shipping Charges
AccruedShippingCharges
1004000
CY2022Q4 ntra Accrued Shipping Charges
AccruedShippingCharges
485000
CY2023Q1 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
5091000
CY2022Q4 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
4319000
CY2023Q1 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
10184000
CY2022Q4 ntra Accrued Specimen Service Fees
AccruedSpecimenServiceFees
6631000
CY2023Q1 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
11373000
CY2022Q4 ntra Accrued Clinical Trials And Studies
AccruedClinicalTrialsAndStudies
23301000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9308000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q1 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1777000
CY2022Q4 ntra Accrued Fixed Asset Purchases
AccruedFixedAssetPurchases
1821000
CY2023Q1 ntra Accrued Interest
AccruedInterest
2695000
CY2022Q4 ntra Accrued Interest
AccruedInterest
1078000
CY2023Q1 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
4628000
CY2022Q4 ntra Other Accrued Sundry Expenses Current
OtherAccruedSundryExpensesCurrent
4022000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
118638000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
144214000
CY2022Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
18948000
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17210000
CY2023Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
2384000
CY2022Q1 ntra Insurance Carrier Reserves Additions
InsuranceCarrierReservesAdditions
3502000
CY2023Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
350000
CY2022Q1 ntra Insurance Refunds To Carriers
InsuranceRefundsToCarriers
1991000
CY2023Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
6711000
CY2022Q1 ntra Insurance Carrier Reserves Released
InsuranceCarrierReservesReleased
1395000
CY2023Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
14271000
CY2022Q1 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
17326000
CY2022Q1 ntra Noncash Investing Activities Related To Right Of Use Assets
NoncashInvestingActivitiesRelatedToRightOfUseAssets
7500000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
9308000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7639000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
73854000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76577000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
83162000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
84216000
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0667
CY2023Q1 us-gaap Lease Cost
LeaseCost
3800000
CY2022Q1 us-gaap Lease Cost
LeaseCost
3300000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2200000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2800000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
10266000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16007000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
16352000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16732000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13676000
CY2023Q1 ntra Lessee Operating Lease Liability Payments Due Year Five And After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
33998000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
107031000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
23869000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
83162000
CY2022Q4 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
30000000.0
CY2022Q4 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
100000000.0
CY2023Q1 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
80000000.0
CY2023Q1 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
70000000.0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
160000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
179000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23412000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21423000

Files In Submission

Name View Source Status
0001558370-23-008938-index-headers.html Edgar Link pending
0001558370-23-008938-index.html Edgar Link pending
0001558370-23-008938.txt Edgar Link pending
0001558370-23-008938-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntra-20230331.xsd Edgar Link pending
ntra-20230331x10q.htm Edgar Link pending
ntra-20230331xex10d1.htm Edgar Link pending
ntra-20230331xex31d1.htm Edgar Link pending
ntra-20230331xex31d2.htm Edgar Link pending
ntra-20230331xex32d1.htm Edgar Link pending
ntra-20230331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
ntra-20230331_def.xml Edgar Link unprocessable
ntra-20230331_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ntra-20230331_lab.xml Edgar Link unprocessable
ntra-20230331_pre.xml Edgar Link unprocessable
ntra-20230331x10q_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending